GLP‑1 hair loss: what the evidence says.

What the labels report

The labels list hair loss among the adverse reactions reported in trials, and they give the rates by treatment group. The Wegovy® label says: “In a pool of studies 2, 3, and 4, hair loss was reported in 3.3% of patients treated with WEGOVY 2.4 mg (4% female, 0.9% male) and in 1% of patients treated with placebo (2% female, 0 male).” The Zepbound® label says: “In a pool of Study 1 and 2, hair loss was reported more frequently in female than male patients in the ZEPBOUND (7.1% female versus 0.5% male) and placebo (1.3% female versus 0% male) treatment groups.”

Those numbers describe trial populations, not a prediction. They also show a pattern that the reviews discuss: the rates are higher in female participants, and higher with the medication than with placebo. The labels do not say that the hair loss is permanent, and they do not give a mechanism.

What the labels do say is that hair loss was associated with weight reduction. That sentence is important because it points away from a simple direct-to-follicle explanation and toward the metabolic context of rapid weight change.

What the review found

A 2026 systematic review searched four databases and included 24 studies. It concluded that “Accumulating evidence from pharmacovigilance databases and clinical cohorts suggests an increased risk of hair loss with certain GLP‑1 RAs, particularly semaglutide and tirzepatide.” The review also found that “Rapid weight loss emerged as a potential contributor, particularly for telogen effluvium” and that the evidence does not establish causality.

Telogen effluvium is a diffuse shedding that follows a stressor by roughly two to three months. The stressor can be illness, surgery, childbirth, severe restriction or rapid weight change. The hair cycle shifts, more hairs enter the resting phase, and the shedding appears later than the event that caused it. The review notes that the timeline is consistent with this pattern for many GLP‑1 cases.

The other common pattern is androgenetic alopecia, a patterned thinning that follows a different course. The review describes telogen effluvium as typically self-limited and reversible, with improvement over months, while patterned loss can persist. A dermatologist can distinguish the two with a history and an examination, and sometimes a hair-pull test or blood tests. The label’s percentage does not tell you which pattern you have.

The review’s counseling section is practical: people starting semaglutide or tirzepatide can be told that diffuse, non-scarring shedding is possible, especially with rapid weight change, and that most reported cases resemble telogen effluvium. It also notes that the evidence is limited by underreporting and differences in study design. That is a more honest framing than either “it is nothing” or “the drug causes baldness.” It also gives a person something to do: record the onset, the pattern and the weight timeline, and ask for an assessment if the shedding persists or is patterned. The record is not a diagnosis, but it is a better starting point than a memory of “it started a while ago,” and it takes only a line a week to keep the timeline going week by week. The rest can wait for the visit.

Not every study agrees. The review describes conflicting pharmacovigilance results and differences in study design, comparator groups and outcome definitions. A meta-analysis cited in the review reported a three-fold increased risk of alopecia across randomized trials, with moderate-to-high heterogeneity. That is a signal worth taking seriously, not a settled mechanism.

What to record

• When the shedding startedThe month, not just “recently.” Telogen effluvium usually appears months after its trigger, so the timeline matters.
• The patternDiffuse shedding across the scalp is different from a receding hairline or a patch. The review distinguishes telogen effluvium from patterned androgenetic alopecia.
• The rate of weight changeWeight and dates, not just the total. A study of weight-loss-associated telogen effluvium found a mean weight loss of 15.21% at a mean rate of 3.54 kg per month.
• Other possible triggersIllness, surgery, childbirth, a new medication, severe restriction, a stressful period. The hair cycle does not label its cause.
• Nutrition and blood testsIf your prescriber orders them, keep the results with the record. Iron, thyroid, vitamin D and other factors can contribute to shedding.
• PhotographsThe same angle and lighting, once a month. A photograph is a better comparison than a memory of the bathroom mirror.

Max HP can keep the hair-loss check‑in beside the dose and weight history, so the timeline is visible in one place. The app does not diagnose the type of hair loss. It records what you notice and when.

When to get help

The review suggests a dermatology referral when hair loss persists beyond six to nine months, shows a patterned loss or rapid miniaturization, comes with scalp itch or inflammation, or causes significant diagnostic uncertainty. Those are clinical thresholds, not a reason to wait if the shedding is distressing.

Hair loss itself is not usually an emergency. The labels also list signs that are, and they apply here as they do to any GLP‑1 question. The Wegovy® Medication Guide says: “Stop using WEGOVY and get medical help right away, if you have any symptoms of a serious allergic reaction including: swelling of your face, lips, tongue or throat; severe rash or itching; very rapid heartbeat; problems breathing or swallowing; fainting or feeling dizzy.” If any of those appear, contact your prescriber, or get emergency help.

Questions

Is hair loss a known side effect of GLP‑1 medications?

Yes. Hair loss appears in the labels and in trial adverse-reaction tables. The rates are higher with semaglutide and tirzepatide than with placebo in the trials cited, and higher in female participants.

Is it permanent?

The review describes most reported cases as telogen effluvium, which is typically self-limited and reversible, with shedding appearing about two to three months after the trigger. Patterned hair loss can have a different course. A dermatologist can assess the type.

Is it caused by the medication or by weight loss?

The evidence points to rapid weight change as a major contributor, and the labels associate hair loss with weight reduction. A direct drug effect has not been established. The answer can be both, and the distinction is a clinical one.

What can I do if I notice shedding?

Record the start date, the pattern and the weight history, and raise it with your prescriber. If the shedding persists, is patterned, or comes with scalp itch or inflammation, ask about a dermatology referral.

Sources

1. Gupta AK, et al. “GLP‑1 therapies and hair loss: A systematic review of current evidence and implications for counseling.” Science Progress 109, no. 2 (2026). Read 4 November 2026.
2. Kang D-H, et al. “Telogen Effluvium Associated With Weight Loss: A Single Center Retrospective Study.” Annals of Dermatology 36, no. 6 (2024): 384–388. Read 4 November 2026.
3. Wegovy® (semaglutide) prescribing information and Medication Guide⁠, DailyMed. Revised June 2026. Read 3 November 2026.
4. Zepbound® (tirzepatide) prescribing information⁠, DailyMed. Revised August 2026. Read 3 November 2026.

Read more

• GLP‑1 muscle mass: what the trials measured
• Why your weight jumps
• What to track on a GLP‑1
• Free printable symptom diary